Medicure Inc. MPH.V

MPH.V Company Overview

Medicure Inc. is a Canadian pharmaceutical company focused on developing, acquiring, and commercializing human therapeutics primarily for cardiovascular and related diseases. The company operates in the specialty pharmaceutical industry and derives most of its revenue from the commercialization of prescription cardiovascular products in the United States. Medicure’s core business centers on hospital-based and acute care therapies, with a strategic emphasis on niche pharmaceutical products that address unmet clinical needs. Its flagship commercial product has been AGGRASTAT (tirofiban hydrochloride), an antiplatelet agent used in acute coronary syndrome treatment settings.

The company was founded in 1997 and is headquartered in Winnipeg, Manitoba, Canada. Medicure evolved from an early-stage drug development company into a commercial-stage pharmaceutical business through product licensing, acquisitions, and commercialization partnerships. Over time, the company shifted its focus toward revenue-generating cardiovascular assets and U.S. market commercialization, supported by acquisitions and licensing arrangements. Public filings and company disclosures indicate that Medicure’s strategy has prioritized targeted specialty products over broad-based pharmaceutical expansion.